Larger studies and long‐term follow‐up are needed to confirm the most predictive biomarkers of patient response to neoadjuvant PD‐1 blockade combined with targeted chemotherapy for treating patients with locally advanced pMMR/MSS CRC, and to examine the associations between the pathologic response resulting from this combined strategy and disease‐free and OS. The gene discussed is RPL17; the disease is colorectal carcinoma.